The research company Hamlet Biopharma has entered into a collaboration agreement with the South Korean biotech company Immunoforge to develop a new method of administration for the peptide drug NZX, which is to be used for the treatment of tuberculosis patients. This is stated in a press release.The parties will jointly own the future rights to the results of the collaboration as well as future patent rights. NZX has shown promising effects in animal models, both against antibiotic-sensitive and antibiotic-resistant Mycobacterium tuberculosis bacteria.No financial details are disclosed.